Summary

GlobalDatas pharmaceuticals report, Afinitor (Breast Cancer) Analysis and Forecasts to 2020 provides Afinitor sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

• Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
• Analysis and review of Afinitor including sales data 
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis of Afinitor including efficacy, safety, pricing, competition and other details which influence its sales potential
• Detailed sales forecast for 2013-2020 for Afinitor in the seven major markets

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

List of Tables

Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Table 3: Five-Year Relative Survival Rates, By Stages 14
Table 4: Approval Status of Afinitor 30
Table 5: Drug Risk Benefit Score of Afinitor 31
Table 6: Annual Cost of Therapy of Afinitor 34
Table 7: Afinitor, Breast Cancer, Global, Sales Forecasts ($m), 20132020 35
Table 8: Afinitor, Breast Cancer, the US, Sales Forecasts ($m), 20132020 36
Table 9: Afinitor, Breast Cancer, the UK, Sales Forecasts ($m), 20132020 37
Table 10: Afinitor, Breast Cancer, France, Sales Forecasts ($m), 20132020 38
Table 11: Afinitor, Breast Cancer, Germany, Sales Forecasts ($m), 20132020 39
Table 12: Afinitor, Breast Cancer, Italy, Sales Forecasts ($m), 20132020 40
Table 13: Afinitor, Breast Cancer, Spain, Sales Forecasts ($m), 20132020 41
Table 14: Afinitor, Breast Cancer, Japan, Sales Forecasts ($m), 20132020 42

List of Figures

Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Figure 3: Top 10 Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 9
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 11
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 12: Broad Classification of Breast Cancer, By Type 15
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 14: Classification of Invasive Breast Cancer, By Stages 16
Figure 15: Classification of Invasive Breast Cancer, By Treatment 16
Figure 16: Classification of Metastatic or Advanced Breast Cancer 16
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 17
Figure 18: Classification of Locally Advanced Breast Cancer 17
Figure 19: Metastatic Breast Cancer Classification 17
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 18
Figure 21: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 19
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 19
Figure 23: Treatment Options, DCIS Breast Cancer 20
Figure 24: Treatment Options, LCIS Breast Cancer 21
Figure 25: Treatment Options, Stages I, II and IIIA 21
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 22
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 22
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 23
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 24
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 24
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 26
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 27
Figure 33: Drug Model Diagram of Afinitor in the US, EU and Japan 33
Figure 34: Afinitor, Breast Cancer, Global, Sales Forecasts ($m), 20132020 35
Figure 35: Afinitor, Breast Cancer, the US, Sales Forecasts ($m), 20132020 36
Figure 36: Afinitor, Breast Cancer, the UK, Sales Forecasts ($m), 20132020 37
Figure 37: Afinitor, Breast Cancer, France, Sales Forecasts ($m), 20132020 38
Figure 38: Afinitor, Breast Cancer, Germany, Sales Forecasts ($m), 20132020 39
Figure 39: Afinitor, Breast Cancer, Italy, Sales Forecasts ($m), 20132020 40
Figure 40: Afinitor, Breast Cancer, Spain, Sales Forecasts ($m), 20132020 41
Figure 41: Afinitor, Breast Cancer, Japan, Sales Forecasts ($m), 2013-2020 42
Figure 42: Afinitor, Breast Cancer, Global, Sales Distribution by Country ($m), 2020 43
Figure 43: Drug Model Diagram 46
Figure 44: Patients Approved to take the Drug 47